Latham & Watkins Advises the Underwriters in Vor Biopharma’s Initial Public Offering

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, has announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of US$18.00 per share. The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately US$176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets deal team led by partners Peter Handrinos and Nathan Ajiashvili, with associates Matthew DeSilva, Victoria McGrath, and MacLane Taggart.